{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Kura Oncology, Inc."},"Symbol":{"label":"Symbol","value":"KURA"},"Address":{"label":"Address","value":"12730 HIGH BLUFF DRIVE,SUITE 400, SAN DIEGO, California, 92130, United States"},"Phone":{"label":"Phone","value":"+1 858 500-8800"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.kuraoncology.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Kathleen Ford","title":"Chief Operating Officer"},{"name":"Stephen Dale","title":"Chief Medical Officer"},{"name":"Troy E. Wilson","title":"Chairman, President, CEO & Chief Financial Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}